Proteins

Andecaliximab is a recombinant IgG4 monoclonal antibody that targets matrix metalloproteinase 9 (MMP9). Andecaliximab has demonstrated anti-fibrotic efficacy in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used for research on gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based bispecific antibody that targets the near-membrane extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. Additionally, Cevostamab promotes effective synapse formation, enhancing T cell killing activity against MM tumor cells.

cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of the metalloproteinase ADAM8, with an IC50 value of 182 nM. It has potential applications in inflammatory diseases and cancer.

EWP 815 is a disulfide analogue and an effective inhibitor of Ins(1,4)P2 phosphatase and Ins(1,4,5)P3 5-phosphatase. It also participates in inhibiting the activity of dopamine beta-hydroxylase in vivo.

Foralumab (NI-0401) is an orally effective humanized monoclonal antibody that targets CD3. Foralumab can modulate the immune response of human cells reconstructed from hematopoietic stem cells in NSG mice.

HKB99 is a conformational inhibitor of phosphoglycerate mutase 1 (PGAM1), which is a glycolytic enzyme. HKB99 inhibits the formation of invasive pseudopodia and increases the level of plasminogen activator inhibitor-2 (PAI-2). It also increases oxidative stress, activates JNK/c-Jun, and inhibits AKT and ERK. HKB99 can be used for research on non-small cell lung cancer (NSCLC).

JMS-053 is an effective, selective, and reversible inhibitor of PTP4A. It inhibits PTP4A1, PTP4A2, PTP4A3, CDC25B and DUSP3 with IC50 values of 29.1 nM, 48.0 nM, 34.7 nM, 92.6 nM and 207.6 nM respectively. JMS-053 can inhibit cancer cell migration and spheroid growth while reducing the growth of ovarian tumors in vivo.

JUN-1111 is an irreversible selective inhibitor of Cdc25 phosphatase, with IC50 values of 0.38, 1.8, 0.66, 28 and 37 μM for Cdc25A, Cdc25B, Cdc25C, VHR and PTP1B respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases and reduces the expression of phosphoCdk1.

Loncastuximab tesirine is an antibody-active molecule conjugate (ADC) that targets human cluster of differentiation 19 (CD19). Once bound to CD19 on the cell membrane, Loncastuximab tesirine is rapidly internalized, leading to cell death. Loncastuximab tesirin induces apoptosis and can be used for research on diffuse large B-cell lymphoma.

MMP2-IN-1 is a moderately effective inhibitor of MMP2, with an IC50 of 6.8 μM. MMP2-IN-1 exhibits significant anti-proliferative activity in certain cancer cells by blocking the cell cycle and inducing apoptosis.

MMP-7-IN-1 is an effective and selective inhibitor of MMP-7 (IC50=10 nM), with IC50>11 mM for MMP-1, -2, -3, -8, -9, and -13. MMP-7 is a potential target for diseases such as cancer and fibrosis.

Muromonab is a monoclonal antibody that targets the CD3 receptor. It can block all cytotoxic T cell functions. Muromonab is also used as an immunosuppressant to reduce acute solid organ transplant rejection reactions.

MY33-3 is an effective and selective inhibitor of protein tyrosine phosphatase RPTPβ/ζ, with an IC50 value of ~0.1 μM. MY33-3 also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate neuroinflammation and cognitive dysfunction caused by Sevoflurane.

NFF-3 TFA peptide is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 and is hydrolyzed by them. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. By labeling NFF-3 TFA with CyDye Cy3/Cy5Q, fluorescence can be generated in cell experiments to detect cellular activity.

PRL-3 Inhibitor 2 (compound 2) is an effective inhibitor of PRL-3, with an IC50 value of 28.1 μM.

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2. Siplizumab can deplete T cells, reduce T cell activation, inhibit T cell proliferation and enrich naïve and bona fide regulatory T cells.

SPAA-52 is a low molecular weight protein tyrosine phosphatase (LMW-PTP) inhibitor with oral activity, competitive and reversible properties (IC50=4 nM, Ki=1.2 nM). SPAA-52 can be used for research on diabetes.

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that can bind to both GPRC5D (a member of the G protein-coupled receptor family C5) and CD3, inducing T cell-mediated killing of MM cells expressing GPRC5 through recruitment and activation of T cells. Talquetamab (JNJ-64407564) has anti-tumor activity.

Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADC) that targets c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody, and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for cancer research.

Teplizumab (MGA-031) is a monoclonal antibody that targets human CD3 and is of the Fc receptor type, non-binding subtype. Teplizumab can alleviate the loss of function in beta cells and is used for research on type 1 diabetes.

Uralenol is a natural PTP1B inhibitor (IC50=21.5 μM) derived from Broussonetia papyrifera. In many cellular and biochemical studies, PTP1B has been shown to play a major role in the dephosphorylation of insulin receptors.

FN-439 TFA is a selective collagenase-1 inhibitor.

ML 400 is a potent and selective LMPTP inhibitor with an IC50 value of 1680 nM.

KLH45b is an inhibitor of DDHD2 (DDHD domain containing 2).